Implementation of Precision Medicine in High-risk Prostate Cancer

Condition(s) studied

Investigational drug(s) / intervention(s)

High-risk treatment SOC: radiotherapy (RT) + ADT (3 years) + Abiraterone acetate (2 years), with radical prostatectomy being an option if contraindication for RT exists)

Active monitoring: Followed with PSA measurements

Radical prostatectomy: Radical prostatectomy

Radiotherapy: Radiotherapy

Androgen deprivation therapy: GnRH agonist + abiraterone acetate/enzalutamide and/or docetaxel

Study summary

This project's objective is to initiate a prospective non-interventional clinical study to perform full molecular characterization and subtyping of the primary tumor prostate cancer patients.

It will identify, compare, and select biomarkers for treatment response in high-risk/metastatic prostate cancer.

Eligibility

Primary outcome measure(s)

• Failure-free survival — From enrollment to 20 years failure-free survival

Trial sites (1)

Other trials for the same condition